Skip to content

Study comparing localised hand psoralen immersion combined with ultraviolet A (PUVA) with localised hand narrowband ultraviolet B (UVB) for the treatment of hand eczema

Observer blind randomised controlled pilot study comparing localised hand PUVA with localised hand narrowband UVB for the treatment of hand eczema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18213910
Enrollment
76
Registered
2012-04-27
Start date
2012-08-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Skin

Interventions

76 participants will be randomised to two groups: Group 1 will receive narrow band UVB phototherapy to the hands. Hands will be exposed to UVB light. Group 2 will receive PUVA phototherapy to the ha

Sponsors

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient has provided written informed consent for participation in the study prior to any study specific procedures 2. Palmar eczema not responding to topical treatments 3. Over 18 years of age 4. No topical treatments (except emollients for 48 hours) 5. No systemic treatments for eczema treatment for 3 months 6. Absence of clinical evidence of bacterial, fungal or viral infection 7. Not pregnant 8. Target Gender: Male & Female

Exclusion criteria

Exclusion criteria: 1. Inability to give informed consent 2. Significant eczema on the dorsal surface of the hands 3. Previous phototherapy within the last 3 months 4. Previous sunbed use within the last 3 months 5. Current involvement in other investigational studies or trials, or involvement within 3 months prior to study entry

Design outcomes

Primary

MeasureTime frame
The proportion of patients responding (clear or almost clear PGA score) Timepoint(s): 12 weeks

Secondary

MeasureTime frame
1. The percentage improvement in the Modified Total Lesion Symptom Score (mTLSS) 2. Dermatology Life Quality Index (DLQI)) 3. Health economic evaluation

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026